Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Clarion Brands Argues NAD Turns Deaf Ear To Tinnitus Claims Review

This article was originally published in The Tan Sheet

Executive Summary

Clarion Brands appeals NAD’s recommendations to discontinue a testimonial and other claims that convey the message its Lipo-Flavonoid Plus substantially reduces or eliminates tinnitus and the symptoms of Ménière’s disease.

You may also be interested in...

Bridges Consumer Startup Reaches Brands For Specialty Conditions In Clarion Deal

Acquiring Clarion Brands from Swander Pace, Bridges Consumer Healthcare adds portfolio of OTC and supplement brands for symptoms including tinnitus, urinary pain relief and excessive sweating.

Hearing Supplement Improvement Claims Don't Echo Separate Ingredient Studies

National Advertising Division says Bel Marra Health's reliance on ingredient studies with dosage or usage that could not translate to the ingredients in the product failed to support its claims. “Without testing that the ingredients in the quantity found in Hearing Rescue have the claimed effect, the results from these studies cannot be used to support qualified claims that the same ingredients in the product reduce the damage caused by repeated noise exposure and improve hearing,” NAD said following a review from a challenge by the Council for Responsible Nutrition.

Nasacort, Flonase Competition Heats Up As Sanofi Appeals NAD Review

Chattem appeals a National Advertising Division decision from a review of advertising comparing its Nasacort nasal allergy spray to GSK’s Flonase. The Sanofi business maintains NAD relied on a “cookbook” approach to determine whether claims for the product are substantiated.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts